CN115043840A - 制备toll样受体调节剂的方法 - Google Patents

制备toll样受体调节剂的方法 Download PDF

Info

Publication number
CN115043840A
CN115043840A CN202210865358.5A CN202210865358A CN115043840A CN 115043840 A CN115043840 A CN 115043840A CN 202210865358 A CN202210865358 A CN 202210865358A CN 115043840 A CN115043840 A CN 115043840A
Authority
CN
China
Prior art keywords
formula
compound
group
reaction mixture
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210865358.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·雅伦
B·H·布朗
J·J·查奥
R·L·哈尔科姆
P·赫尔瓦廷
R·麦克法登
P·罗伊斯勒
E·鲁迪奥
杨红
R·H·C·余
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CN115043840A publication Critical patent/CN115043840A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
CN202210865358.5A 2014-09-16 2015-09-14 制备toll样受体调节剂的方法 Pending CN115043840A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462051044P 2014-09-16 2014-09-16
US62/051,044 2014-09-16
PCT/US2015/050039 WO2016044183A1 (en) 2014-09-16 2015-09-14 Methods of preparing toll-like receptor modulators
CN201580050126.2A CN107074860B (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580050126.2A Division CN107074860B (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法

Publications (1)

Publication Number Publication Date
CN115043840A true CN115043840A (zh) 2022-09-13

Family

ID=54291584

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210865358.5A Pending CN115043840A (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法
CN201580050126.2A Active CN107074860B (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580050126.2A Active CN107074860B (zh) 2014-09-16 2015-09-14 制备toll样受体调节剂的方法

Country Status (20)

Country Link
US (1) US9573952B2 (https=)
EP (3) EP3461828B1 (https=)
JP (4) JP6373490B2 (https=)
KR (3) KR102306860B1 (https=)
CN (2) CN115043840A (https=)
AR (1) AR101882A1 (https=)
AU (2) AU2015318062B2 (https=)
BR (1) BR112017005100A2 (https=)
CA (1) CA2960384C (https=)
EA (1) EA201790373A1 (https=)
ES (3) ES2706527T3 (https=)
IL (1) IL250849A0 (https=)
MX (1) MX2017003288A (https=)
NZ (1) NZ729526A (https=)
PL (2) PL3461828T3 (https=)
PT (2) PT3194402T (https=)
SG (1) SG11201701472VA (https=)
SI (1) SI3461828T1 (https=)
TW (2) TWI692468B (https=)
WO (1) WO2016044183A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2019057158A1 (zh) * 2017-09-22 2019-03-28 江苏恒瑞医药股份有限公司 稠合杂芳基衍生物、其制备方法及其在医药上的应用
WO2023212121A2 (en) * 2022-04-26 2023-11-02 Bigelow Laboratory For Ocean Sciences Methods for producing halogenated compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143724A1 (en) * 2007-04-18 2010-01-13 Kissei Pharmaceutical Co., Ltd. Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
WO2010077613A1 (en) * 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2012087596A1 (en) * 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JP2886570B2 (ja) 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
JPH05320143A (ja) * 1992-03-18 1993-12-03 Mochida Pharmaceut Co Ltd 新規ピリミジン誘導体
TW274550B (https=) 1992-09-26 1996-04-21 Hoechst Ag
US5620978A (en) 1994-01-03 1997-04-15 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6492520B1 (en) 1996-08-06 2002-12-10 Pfizer Inc Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
WO2000000478A1 (en) 1998-06-26 2000-01-06 Bristol-Myers Squibb Pharma Company Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
EP1409487A1 (en) 1999-09-15 2004-04-21 Warner-Lambert Company Llc Pteridinones as kinase inhibitors
US6452325B1 (en) 2000-07-24 2002-09-17 Thermoplastic Processes, Inc. Shatterproofing of fluorescent lamps
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
PT1427730E (pt) 2001-09-04 2006-11-30 Boehringer Ingelheim Pharma Novas di-hidropteridinonas, processo para sua preparação e sua utilização como medicamento
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
BR0318145A (pt) 2003-02-26 2006-02-21 Boehringer Ingelheim Pharma dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento
EP2269638A3 (en) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
EP1888587A1 (en) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
WO2007014838A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
US20070299067A1 (en) 2006-03-08 2007-12-27 Ruiping Liu Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
EP2004193A2 (en) 2006-03-13 2008-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20090227579A1 (en) 2006-06-23 2009-09-10 Astrazeneca Ab Pteridine Derivatives and their Use as Cathespin Inhibitors
ATE543819T1 (de) 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
US20100120799A1 (en) 2007-02-19 2010-05-13 Smithkline Beecham Corporation Purine derivatives as immunomodulators
WO2008113711A1 (en) 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
WO2008124575A1 (en) 2007-04-05 2008-10-16 Smithkline Beecham Corporation Renin inhibitors
WO2008124703A2 (en) 2007-04-05 2008-10-16 Siemens Medical Solutions Usa, Inc. Development of molecular imaging probes for carbonic anhydrase-ix using click chemistry
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
WO2009022185A2 (en) 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
WO2009067547A1 (en) 2007-11-19 2009-05-28 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CN101284810A (zh) 2008-06-02 2008-10-15 秦引林 氰基吡咯烷和氰基噻唑烷衍生物
NO2477987T3 (https=) * 2009-09-14 2018-06-09

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143724A1 (en) * 2007-04-18 2010-01-13 Kissei Pharmaceutical Co., Ltd. Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
WO2010077613A1 (en) * 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2012087596A1 (en) * 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAUL A ROETHLE等: "Identification and Optimization of Pteridinone Toll-Like Receptor-7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 56, no. 18, pages 1 - 29 *

Also Published As

Publication number Publication date
IL250849A0 (en) 2017-04-30
EP3461828A3 (en) 2019-05-01
US9573952B2 (en) 2017-02-21
EP3848375C0 (en) 2023-12-27
TWI692468B (zh) 2020-05-01
JP6373490B2 (ja) 2018-08-15
KR102306860B1 (ko) 2021-09-30
MX2017003288A (es) 2017-06-28
ES2975520T3 (es) 2024-07-08
EP3461828B1 (en) 2020-11-25
JP7333843B2 (ja) 2023-08-25
KR20170048592A (ko) 2017-05-08
JP2018158953A (ja) 2018-10-11
JP6596127B2 (ja) 2019-10-23
JP7063865B2 (ja) 2022-05-09
CA2960384A1 (en) 2016-03-24
AU2018236824B2 (en) 2020-04-23
PT3194402T (pt) 2019-02-11
SG11201701472VA (en) 2017-04-27
EA201790373A1 (ru) 2017-08-31
CN107074860A (zh) 2017-08-18
EP3848375B1 (en) 2023-12-27
NZ729526A (en) 2018-05-25
KR20190053292A (ko) 2019-05-17
AR101882A1 (es) 2017-01-18
CN107074860B (zh) 2022-07-15
KR20210118985A (ko) 2021-10-01
TW202043195A (zh) 2020-12-01
AU2015318062B2 (en) 2018-07-05
EP3848375A1 (en) 2021-07-14
TWI780423B (zh) 2022-10-11
PL3848375T3 (pl) 2024-05-06
KR102457426B1 (ko) 2022-10-24
TW201625524A (zh) 2016-07-16
JP2017526729A (ja) 2017-09-14
CA2960384C (en) 2019-07-23
US20160075707A1 (en) 2016-03-17
JP2019214626A (ja) 2019-12-19
PL3461828T3 (pl) 2021-07-19
WO2016044183A1 (en) 2016-03-24
AU2018236824A1 (en) 2018-10-18
JP2022051834A (ja) 2022-04-01
SI3461828T1 (sl) 2021-01-29
AU2015318062A1 (en) 2017-03-16
EP3194402A1 (en) 2017-07-26
EP3194402B1 (en) 2018-11-21
ES2706527T3 (es) 2019-03-29
KR101978809B1 (ko) 2019-05-15
BR112017005100A2 (pt) 2017-12-05
ES2845205T3 (es) 2021-07-26
PT3461828T (pt) 2021-01-26
EP3461828A2 (en) 2019-04-03

Similar Documents

Publication Publication Date Title
JP7333843B2 (ja) Ｔｏｌｌ様受容体モジュレーターを調製する方法
CN113683614B (zh) 用于治疗正粘病毒感染的稠合三环哒嗪酮化合物
CN116670142A (zh) Mk2抑制剂、其合成和其中间体
HK40077654A (en) Methods of preparing toll-like receptor modulators
HK40051817A (en) Methods of preparing intermediates for toll-like receptor modulators
HK40051817B (en) Methods of preparing intermediates for toll-like receptor modulators
HK1239677A1 (en) Methods of preparing toll-like receptor modulators
HK1239677B (en) Methods of preparing toll-like receptor modulators
HK40005950B (en) Methods of preparing toll-like receptor modulators
HK40005950A (en) Methods of preparing toll-like receptor modulators
HK1239684A1 (en) Methods of preparing toll-like receptor modulators
HK1239684B (en) Methods of preparing toll-like receptor modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40077654

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220913

WD01 Invention patent application deemed withdrawn after publication